Glucocorticoid inhibitors for treatment of prostate cancer
US10919929B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 11, 2014 |
| Grant date | Feb 16, 2021 |
| Priority date | — |
| Expiry date | Dec 11, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/743
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention encompasses the recognition that reproducible and detectable changes in the level and or activity of Glucocorticoid Receptor (GR) are associated with incidence and/or risk of Castration Resistant Prostate Cancer (CRPC) and/or doubly resistant prostate cancer, specifically in individuals having prostate cancer and on antiandrogen therapy, and provides for the use of GR inhibitors to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer. In some embodiments, GR inhibitors also have Androgen Receptor (AR) inhibitory activity or are administered in conjunction with AR inhibitors. The present invention also provides technologies for identification and/or characterization of agents to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer; in some embodiments such agents alter level and/or activity of a GR. In some embodiments, provided agents show effects on a GR's activity of regulating transcription of one or more target genes. The present invention also provides systems for using such agents, for example to treat and/or reduce risk of CRPC and/or doubly resistant prostate cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.